Dr. Roya Tabatabai Sheridan, MD

Dr. Sheridan practices at UC Davis Medical Center in Sacramento, California, part of University of California Health.

Dr. Sheridan's NPI, 1518284918, was assigned on April 23, 2010. Dr. Sheridan graduated from David Geffen School of Medicine at UCLA in 2010. Dr. Sheridan's California license number on file is A118809.

Dr. Sheridan's primary practice is UC Davis Medical Center, at 2315 Stockton Boulevard, Sacramento, CA 95817 in Sacramento County. The practice phone is (916) 734-2011.

Dr. Sheridan's primary practice is UC Davis Medical Center in Sacramento, California, part of University of California Health. Dr. Sheridan is also affiliated with Marshall Medical. The medical group on file is UC Davis Medical Group. Dmand AI also links Dr. Sheridan to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sheridan practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Sheridan's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Sheridan is board certified in hematology by the American Board of Internal Medicine. Dr. Sheridan has a license on file in California.

Dmand AI lists tobacco use among the conditions Dr. Sheridan treats.

CMS data shows 291 Medicare services from Dr. Sheridan across 5 procedure codes in 2024, for 54 Medicare patients. Medicare paid $17,273 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 54 Medicare patients who saw Dr. Sheridan in 2024. The largest group is 65 to 74, with 26 patients. 67% of them have cancer, and 65% have high blood pressure. 37% are also on Medicaid. Their average risk score is 2.75, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sheridan's median patient age at 70, with 53% women.

In 2024, Dr. Sheridan wrote 494 Medicare Part D claims for 50 patients. 87% of them were for generic drugs. CMS names the drug for 319 of them, across 18 drugs with 11 or more claims each, at $131,003 in total drug cost. In 2023, CMS named 266 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Sheridan for performance year 2024, reported as part of a group. Dr. Sheridan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sheridan as offering telehealth.

Dmand AI links 1 paper to Dr. Sheridan in 2023. Dr. Sheridan's most frequent co-authors are Danny Da-Yeh Cheng, MD, Luis Armando Godoy, MD and Robert Justin Knebel.

CMS Open Payments shows 28 general payments to Dr. Sheridan from 6 drug and device companies from 2016 to 2022. Food and beverage make up the largest share, 66% of the total. Eli Lilly and Company paid the most, $618.

Dr. Sheridan graduated from David Geffen School of Medicine at UCLA in 2010.

Dr. Sheridan is in network with 11 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.